The role of factor Xa inhibitors in venous thromboembolism treatment

References

• KearonCAklEAComerotaAJAntithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest2012141Suppl 2e419Se494S22315268
   PubMed Web of Science ®Google Scholar
• ErikssonBIQuinlanDJWeitzJIComparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in developmentClin Pharmacokinet20094812219071881
   PubMed Web of Science ®Google Scholar
• AlexanderJHSinghKPInhibition of Factor Xa: A potential target for the development of new anticoagulantsAm J Cardiovasc Drugs20055527929016156684
   PubMedGoogle Scholar
• RaiRSprengelerPAElrodKCYoungWBPerspectives on factor Xa inhibitionCurr Med Chem2001810111911172669
   PubMed Web of Science ®Google Scholar
• KubitzaDBeckaMWensingGVoithBZuehlsdorfMSafety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 – an oral, direct Factor Xa inhibitor – after multiple dosing in healthy male subjectsEur J Clin Pharmacol20056187388016328318
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceuticals, IncXarelto^®: Highlights of Prescribing InformationJanssen Pharmaceuticals, Inc2011 Available from: http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf#zoom=100Accessed March 28, 2014
   Google Scholar
• Bristol-Myers SquibbEliquis: Highlights of Prescribing InformationBristol-Myers Squibb2014 Available from: packageinserts.bms.com/pi/pi_eliquis.pdfAccessed October 19, 2014
   Google Scholar
• OgataKMendell-HararyJTachibanaMClinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteersJ Clin Pharmacol201050774375320081065
   PubMed Web of Science ®Google Scholar
• MatsushimaNLeeFSatoTWeissDMendellJBioavailability and safety of the factor Xa inhibitor edoxaban and the effects of quinidine in healthy subjectsClinical Pharmacology in Drug Development20132358366
   PubMed Web of Science ®Google Scholar
• FrostCWangJNepalSApixaban, an oral, direct factor Xa inhibitor: single-dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjectsBr J Clin Pharmacol201375247648722759198
   PubMed Web of Science ®Google Scholar
• FrostCYuZShenkerAFood does not affect the pharmacokinetics of apixaban, an oral, factor Xa inhibitorCan J Clin Pharmacol200815e469 Abstract
   Google Scholar
• MendellJTachibanaMShiMKunitadaSEffects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteersJ Clin Pharmacol20115168769420534818
   PubMed Web of Science ®Google Scholar
• FurugohriTIsobeKHondaYDU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profilesJ Thromb Haemost2008691542154918624979
   PubMed Web of Science ®Google Scholar
• CammAJBounameauxHEdoxaban: a new oral direct factor xa inhibitorDrugs201171121503152621861537
   PubMed Web of Science ®Google Scholar
• GulsethMPMichaudJNutescuEARivaroxaban: an oral direct inhibitor of factor XaAm J Health Syst Pharm2008651520152918693206
   PubMed Web of Science ®Google Scholar
• BathalaMSMasumotoHOgumaTHeLLowrieCMendellJPharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor xa inhibitor, in humansDrug Metab Dispos2012402250225522936313
   PubMed Web of Science ®Google Scholar
• EINSTEIN InvestigatorsBauersachsRBerkowitzSDOral rivaroxaban for symptomatic venous thromboembolismN Engl J Med2010363262499251021128814
   PubMed Web of Science ®Google Scholar
• EINSTEIN–PE InvestigatorsBüllerHRPrinsMHOral rivaroxaban for the treatment of symptomatic pulmonary embolismN Engl J Med2012366141287129722449293
   PubMed Web of Science ®Google Scholar
• AgnelliGBullerHRCohenAOral apixaban for the treatment of acute venous thromboembolismN Engl J Med2013369979980823808982
   PubMed Web of Science ®Google Scholar
• Hokusai-VTE InvestigatorsBüllerHRDécoususHEdoxaban versus warfarin for the treatment of symptomatic venous thromboembolismN Engl J Med2013369151406141523991658
   PubMed Web of Science ®Google Scholar
• AgnelliGBullerHRCohenAApixaban for extended treatment of venous thromboembolismN Engl J Med201336869970823216615
   PubMed Web of Science ®Google Scholar
• NutescuEChuatrisornIHellenbartEDrug and dietary interactions of warfarin and novel oral anticoagulants: an updateJ Thromb Thrombolysis20113132634321359645
   PubMed Web of Science ®Google Scholar
• FrostCWangJNepalSEffect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitorJ Clin Pharmacol20094910911130 Abstract
   Web of Science ®Google Scholar
• MendellJZahirHMatsushimaNDrug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitorAm J Cardiovasc Drugs20131333134223784266
   PubMed Web of Science ®Google Scholar
• RuffCTGiuglianoRPAntmanEMEvaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis in Myocardial Infarction study 48 (ENGAGE AF-TIMI 48)Am Heart J201016063564120934556
   PubMed Web of Science ®Google Scholar
• GruberAMarzecUMBuetehornUHansonSPerzbornEPotential of activated prothrombin complex concentrate and activated factor VII to reverse the anticoagulant effects of rivaroxaban in primatesBlood20081121307 abstract 3825
   Web of Science ®Google Scholar
• EerenbergESKamphuisenPWSijpkensMKMeijersJCBullerHRLeviMReversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in health subjectsCirculation20111241573157921900088
   PubMed Web of Science ®Google Scholar
• Daiichi Sankyo IncA Two-part Study in Edoxaban-treated Healthy Subjects to a Punch Biopsy Bleeding Model Establish and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on Anticoagulation Available from: http://clinicaltrials.gov/ct2/show/NCT02047565?term=NCT02047565&rank=1.NLMidentifier:NCT02047565Accessed July 12, 2014
   Google Scholar
• Andexanet alfa: FXa Inhibitor Antidote [webpage on the Internet]South San FranciscoPortola Pharmaceuticals Inc http://www.portola.com/clinical-development/andexanet-alfa-prt4445-fxa-inhibitor-antidote/Accessed June 2, 2014
   Google Scholar
• LuGDeGuzmanFRLakhotiaSHollenbackSJPhillipsDRSinhaURecombinant antidote for reversal of anticoagulation by factor Xa inhibitorsBlood2008112 abstract 983
   Web of Science ®Google Scholar
• ManthaSAnsellJIndirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolismJ Thromb Thrombolys Epub732014
   PubMed Web of Science ®Google Scholar